Intrinsic Value of S&P & Nasdaq Contact Us

Paragon 28, Inc. FNA NYSE

NYSE • Healthcare • Medical - Devices • US • USD

SharesGrow Score
36/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$13.00
-0.7%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Paragon 28, Inc. (FNA) .

Criteria proven by this page:

  • VALUE (35/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
  • Analyst consensus target $13.00 (-0.7% downside) — slight downside risk — the market may be ahead of analyst expectations.

Overall SharesGrow Score: 36/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score
36/100
SG Score
View full scorecard →
VALUE
35/100
Price-to-Earnings & upside
Proven by this page
FUTURE
26/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
55/100
→ Income
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — FNA

Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio4.26
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.66
Book Value / Share$0.00
Revenue / Share$3.07
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$13.00 (-0.7%)

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2019 $0.04 $106.28M $3.12M 2.9%
2020 $0.04 $110.98M $2.69M 2.4%
2021 $-0.18 $147.46M $-13.69M -9.3%
2022 $-0.88 $181.38M $-67.33M -37.1%
2023 $-0.70 $216.39M $-57.53M -26.6%
2024 $-0.66 $256.18M $-54.64M -21.3%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message